Skip to main content

Reversing the advantage of cancers with Hypoxia and Homologous Recombination Defect (HRD) by using a pan-cancer, composite, lesions-specific biomarker

Project description

Cancer biomarkers for predicting treatment outcome

Drug effectiveness is often hampered by systemic cytotoxicity. Anti-cancer drugs exhibit adverse effects by damaging normal tissues and organs. Prodrugs that can be activated by specific stimuli to exert their pharmacological effect have emerged as safer options. CP-506 is such a prodrug that is activated by the low oxygen levels of tumours (hypoxia) known to promote cancer aggressiveness and therapy resistance. CP-506 causes DNA damage so tumours defective in DNA repair pathways are at a disadvantage. The mission of the ERC-funded ReverseTheAdvantage project is to develop a solution that can identify tumours that exhibit both hypoxia and defects in DNA damage repair to predict the efficacy of CP-506 treatment.


Net EU contribution
€ 150 000,00
Minderbroedersberg 4
6200 MD Maastricht

See on map

Limburg (NL) Zuid-Limburg
Activity type
Higher or Secondary Education Establishments
Other funding
No data